Biotheus pronounces the closing of a brand new spherical of financing co-led by Normal Atlantic and IDG Capital
ZHUHAI, China, March 2, 2021 / PRNewswire / – Biotheus Declares Profitable Completion of Fourth Spherical of Funding, Co-led by Normal Atlantic, a Main International Progress Fairness Investor, and IDG Capital, a Main International Funding Agency . Different new buyers embody Kunlun Capital, CPE and Cowin Capital, with participation from former buyers Spotlight Capital, Shiyu Capital, New Alliance Capital, Huajin Funding, and many others.
Based in 2018, Biotheus is an organization in medical growth whose mission is to deal with most cancers and autoimmune illnesses by means of next-generation therapies. That is supported by the corporate’s product portfolio, which incorporates greater than 10 new monoclonal and multispecific antibodies. Biotheus at the moment has two bispecific antibodies in section I medical growth for the remedy of most cancers, and a 3rd IND utility was submitted on the finish of 2020. With this new funding, Biotheus will additional enhance its funding in its analysis actions with the intention of to have 5 new ones. medicine in medical growth by the tip of 2021, and drive a number of packages in the direction of superior medical growth.
Concerning this spherical of financing, Mr. Xiaolin liu, Chairman and CEO of Biotheus, mentioned: “We’re happy that our efforts have been acknowledged and supported by main buyers akin to Normal Atlantic and IDG Capital. The continued help of our earlier buyers can also be a testomony to the progress, execution and energy of our enterprise. of our pipeline. This spherical of funding will fund the event of our present product portfolio and the development of our manufacturing facility. With the unwavering help of all our buyers, we’ll totally lead the event of our product portfolio and strengthen our place within the international most cancers immunotherapy market, and produce much-needed revolutionary remedies and choices to a wider inhabitants of most cancers sufferers. . “
Mr. Lefei Solar, Director Normal and Head of Well being for China at Normal Atlantic, added: “In a brief time frame, Biotheus has developed a differentiated and aggressive pipeline of subsequent technology therapies, supported by an environment friendly R&D engine and a number one founding crew with a profitable observe report within the growth of antibodies. Collectively, we consider that Biotheus is firmly positioned as an rising participant within the international biopharmaceutical panorama. We look ahead to supporting Biotheus and its administration crew to speed up the event of their broad product portfolio and advance most cancers remedies. revolutionary and commercially important. “
“Directed by Mr. Xiaolin liu, the core Biotheus crew has intensive expertise within the growth of latest antibody medicine, ”mentioned Mr. Tao Huang, Vice-president of IDG Capital. “Biotheus has constructed a number of important drug growth platforms and a product pipeline with a robust aggressive benefit. The development of their manufacturing base has additionally began. We consider that Biotheus has important development potential.”
About Biotheus
Based in 2018, Biotheus is an rising biotechnology firm centered on curing malignant tumors and autoimmune illnesses. Biotheus is engaged within the analysis and growth, and commercialization of revolutionary, first-class biologics, primarily by means of the invention of next-generation multispecific antibodies. Biotheus has accomplished 4 rounds of funding. As well as, Biotheus has acquired help from the Zhuhai authorities by means of a variety of initiatives and insurance policies that stimulate native innovation.
About Normal Atlantic
Normal Atlantic is a number one international non-public fairness agency offering capital and strategic help to development firms. Based in 1980, Normal Atlantic combines a collaborative international strategy, trade experience, a long-term funding horizon and a deep understanding of development drivers to companion with nice entrepreneurs and administration groups to create main firms. of the market everywhere in the world. Normal Atlantic has over 175 funding professionals based mostly in new York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico, Bombay, Munich, Palo Alto, São Paulo, Shanghai and Singapore. For extra data on Normal Atlantic, please go to the web site: www.generalatlantic.com.
About IDG Capital
Based in 1993, IDG Capital was the primary firm to introduce international enterprise capital in China. IDG Capital has at all times sought long-term worth investments and has centered on growing extraordinary firms by means of our experience in non-public fairness and enterprise capital. After almost 30 years of growth, IDG capital has gathered property underneath administration of roughly 150 billion RMB, has invested over 1,000 firms and with over 200 profitable exits. IDG Capital focuses on main firms in TMT, New Customers and Companies, Leisure, Healthcare, Superior Manufacturing and Clear Vitality, firms growing from early stage to early stage. development, IPOs and mergers and acquisitions. IDG Capital’s funding portfolio within the healthcare sector consists of: MGI Tech, Colortech Bio, Ping a very good physician, Edigene, HiFiBio, Biosciences Analytiques, Zhenge Biotech, Gensciences, Microtech Medical, Keya Medical, Accutar Biotech and Lyvgen.
About Kunlun Capital
Kunlun Capital was based in 2015 and focuses on investing in technologically revolutionary firms. It operates in a two-currency USD and RMB mannequin. The present scale of asset administration exceeds 10 billion RMB. Kunlun Capital pays explicit consideration to revolutionary enterprise fashions based mostly on expertise, merchandise and information, and seeks entrepreneurial groups with globalization potential and localization capabilities by deciding on main firms within the subdivisions. Kunlun Capital has successively invested in Opera, DaDa, Pony.AI, KEYA Medical, MicroPort CardioFlow, EdiGene, OBiO, PingCap and different firms.
About CPE
CPE is another asset supervisor with China expertise and, on the identical time, a global perspective. With a long-term imaginative and prescient and a worth funding technique, CPE offers revolutionary funding options to main firms within the following 5 key sectors: healthcare, shopper and web, expertise and trade, software program and enterprise companies and immovable. With at the moment profitable long-term efficiency, CPE’s funds underneath administration are backed by greater than 200 home and worldwide institutional buyers throughout North America, Europe, Asia and the Center East. The core funding crew has revamped 200 investments globally and has an excellent observe report in a number of USD and RMB funds, with complete property underneath administration exceeding 100 billion RMB, permitting the corporate to build up key information of the sector and an in depth business community. With a stable funding and analysis course of, robust trade experience {and professional} portfolio administration capabilities, CPE builds long-term relationships with its portfolios with the intention to drive their worth creation and sustainable development.
About Cowin Capital
Cowin Capital Group was established in 2000 12 months as From China one of many earliest skilled Chinese language non-public fairness funding firm market. Cowin Capital has 20 years of expertise in capital administration, of which the dimensions of capital administration was among the many finest within the discipline with greater than 20 billion RMB underneath and generated extraordinary returns. The Cowin Capital group focuses on investing in long-term pioneer firms, supporting the long-term growth of firms. Cowin has invested over 500 firms over time and over 90 firms have gone public.
SOURCE Biotheus Inc.